Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
- Registration Number
- NCT00387270
- Lead Sponsor
- Medivation, Inc.
- Brief Summary
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
- Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36
- Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale
Exclusion Criteria
- Clinical evidence of unstable medical illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A Dimebon Dimebon
- Primary Outcome Measures
Name Time Method Dose-limiting toxicities 7 days
- Secondary Outcome Measures
Name Time Method Unified Huntington's Disease Rating Scale 7 days
Trial Locations
- Locations (1)
Huntington Study Group
🇺🇸Rochester, New York, United States